News

Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved the brand name Galafold. Amicus Therapeutics chairman and CEO John Crowley said:

The VX-745 is an oral brain penetrant, which is highly selective and a potent inhibitor of the alpha isoform of the protein enzyme p38 mitogen activated protein kinase

Relistor is indicated for OIC treatment when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The approval of Relistor is

Fluzone Quadrivalent, a commercially available vaccine, is the active comparator in the VAX2012Q clinical trial. Around 450 healthy adults, aged 18-64, will be enrolled for the trial. They

The original collaboration, initiated in 2013, was focused on applying gene therapy technology to genetically modify a patient’s own T cells to target and destroy cancer cells. BCMA

The required regulatory documents for the merger were approved by the New York State Attorney General on May 20, 2015. The combined entity, which will carry on the

The acquisition brings to Biota AP611074, a patented, direct-acting antiviral in clinical development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent

The open-label, single-arm, Phase 2 study is a thorough PK/PD assessment designed to: (1) measure the effects of CPX-351 on cardiac repolarization following the first induction cycle of

The Rapporteur (from Portugal) and Co-Rapporteur (from the United Kingdom) are the two appointed members of the Committee for Medicinal Products for Human Use (CHMP) who would lead